{"id":"tadalafil","brandName":"Cialis","genericName":"tadalafil","companyId":"eli-lilly","companyName":"Eli Lilly","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drugClass":"Phosphodiesterase 5 Inhibitor [EPC]"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"11666 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"10691 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"7803 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"6498 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"5900 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5836 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"5434 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"5176 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"4224 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"4201 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nasal congestion","drugRate":"","severity":"common","organSystem":""},{"effect":"Flushing","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain in limb","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute coronary syndrome","Acute nephropathy","Acute peptic ulcer","Alcohol intoxication","Anterior ischemic optic neuropathy","Aortic valve stenosis","Blood coagulation disorder","Cerebrovascular accident","Chronic heart failure","Exercise-induced angina","Fibrosis of corpus cavernosum","Functional visual loss","Hb SS disease","Hearing loss","Hepatic failure","Hypertensive urgency","Idiopathic hypertrophic subaortic stenosis","Induratio penis plastica","Leukemia, disease","Life-Threatening Cardiac Arrhythmias","Low blood pressure","Multiple myeloma","Myocardial infarction","Penis bent","Pigmentary Retinopathy","Priapism","Seizure disorder","Severe Autonomic Insufficiency"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Gastroesophageal reflux disease","drugRate":"","severity":"serious"},{"effect":"Vomiting","drugRate":"","severity":"serious"},{"effect":"Arthralgia","drugRate":"","severity":"serious"},{"effect":"Muscle spasm","drugRate":"","severity":"serious"}]},"trials":["NCT00626665","NCT03229889","NCT03246880","NCT00506701","NCT01903083","NCT01197469","NCT05494567","NCT02247505","NCT02653833","NCT06290713","NCT01544998","NCT02431754","NCT01743911","NCT02999906","NCT02611336","NCT05458232","NCT07447518","NCT00382135","NCT00617305","NCT00750308","NCT06717711","NCT05179876","NCT02645890","NCT04164355","NCT05955001","NCT07391579","NCT02544880","NCT06553924","NCT01564303","NCT06491108","NCT05466695","NCT00540124","NCT00274430","NCT01937871","NCT01484431","NCT06962462","NCT00421083","NCT04946162","NCT04491773","NCT00547287","NCT01130532","NCT07466030","NCT02554045","NCT01553981","NCT06707181","NCT00668109","NCT01122264","NCT01858558","NCT07231185","NCT05823506"],"indications":{"approved":[{"name":"Benign prostatic hyperplasia","diseaseId":"benign-prostatic-hyperplasia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Impotence","diseaseId":"impotence","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary hypertension","diseaseId":"pulmonary-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Formulation","number":"11975006","applicant":"CMP DEVELOPMENT LLC","territory":"US","tradeName":"TADLIQ","expiryDate":"2038-12-24"},{"type":"Formulation","number":"12186322","applicant":"CMP DEVELOPMENT LLC","territory":"US","tradeName":"TADLIQ","expiryDate":"2038-12-24"},{"type":"Formulation","number":"11382917","applicant":"CMP DEVELOPMENT LLC","territory":"US","tradeName":"TADLIQ","expiryDate":"2038-12-24"},{"type":"Formulation","number":"11666576","applicant":"CMP DEVELOPMENT LLC","territory":"US","tradeName":"TADLIQ","expiryDate":"2038-12-24"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00626665","phase":"Phase 3","title":"Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","isPivotal":true,"enrollment":25,"indication":"Raynaud Disease","completionDate":"2008-04"},{"nctId":"NCT03229889","phase":"Phase 4","title":"Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy and Endoscopic-Guided Percutaneous Nephrolithotomy: A Randomized Double-Blind Placebo Controlled Trial of Tadalafil, Tamsul","status":"COMPLETED","sponsor":"University of California, Irvine","isPivotal":false,"enrollment":220,"indication":"Nephrolithiasis","completionDate":"2022-03-24"},{"nctId":"NCT03246880","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":true,"enrollment":455,"indication":"Benign Prostatic Hyperplasia","completionDate":"2016-05"},{"nctId":"NCT00506701","phase":"NA","title":"Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Herlev Hospital","isPivotal":false,"enrollment":0,"indication":"Chronic Obstructive Lung Disease","completionDate":"2010-02"},{"nctId":"NCT01903083","phase":"Phase 1","title":"Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.","status":"COMPLETED","sponsor":"Providence Health & Services","isPivotal":false,"enrollment":10,"indication":"Locally Advanced Malignant Neoplasm","completionDate":"2017-12"},{"nctId":"NCT01197469","phase":"Phase 2","title":"Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension?","status":"COMPLETED","sponsor":"University of Dundee","isPivotal":false,"enrollment":120,"indication":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","completionDate":"2012-09"},{"nctId":"NCT05494567","phase":"Phase 4","title":"Efficacy of Tadalafil and Solifenacin Versus Tamsulosin and Solifenacin Combination Therapy for the Treatment of Benign Prostatic Hyperplasia With Overactive Bladder: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Mansoura University","isPivotal":false,"enrollment":60,"indication":"Benign Prostatic Hyperplasia, Overactive Bladder","completionDate":"2022-08"},{"nctId":"NCT02247505","phase":"Phase 1","title":"A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tadalafil on Tamsulosin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":false,"enrollment":29,"indication":"Healty Male Volunteers","completionDate":"2014-12"},{"nctId":"NCT02653833","phase":"EARLY/Phase 1","title":"Skeletal Muscle Blood Flow in Becker Muscular Dystrophy","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","isPivotal":false,"enrollment":6,"indication":"Muscular Dystrophy","completionDate":"2018-09-01"},{"nctId":"NCT06290713","phase":"Phase 2","title":"Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)","status":"RECRUITING","sponsor":"University of Florida","isPivotal":false,"enrollment":50,"indication":"Duchenne Muscular Dystrophy, Duchenne Disease","completionDate":"2026-11"},{"nctId":"NCT01544998","phase":"Phase 1","title":"To Define the Role of PDEV in Mediating the Decreased GFR and Attenuated Renal Sodium and cGMP Excretory Response to Acute Saline Volume Expansion in PSD and PDD With Renal Dysfunction.","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":43,"indication":"Congestive Heart Failure","completionDate":"2014-08"},{"nctId":"NCT02431754","phase":"Phase 4","title":"A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":171,"indication":"Benign Prostatic Hyperplasia","completionDate":"2016-02"},{"nctId":"NCT01743911","phase":"NA","title":"Phosphodiesterase-5 Inhibitor (Tadalafil) Two Weeks Administration Period Effects in Left Ventricle Diastolic Dysfunction and BNP Levels in Resistant Hypertensive Patients","status":"COMPLETED","sponsor":"University of Campinas, Brazil","isPivotal":false,"enrollment":20,"indication":"Hypertension","completionDate":"2012-08"},{"nctId":"NCT02999906","phase":"Phase 3","title":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambr","status":"WITHDRAWN","sponsor":"United Therapeutics","isPivotal":true,"enrollment":0,"indication":"Pulmonary Arterial Hypertension","completionDate":"2022-06"},{"nctId":"NCT02611336","phase":"Phase 2","title":"Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodieste","status":"COMPLETED","sponsor":"Andrea M. Isidori","isPivotal":false,"enrollment":15,"indication":"Acromegaly Cardiomyopathy","completionDate":"2021-06"},{"nctId":"NCT05458232","phase":"N/A","title":"Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults","status":"WITHDRAWN","sponsor":"University of Arkansas","isPivotal":false,"enrollment":0,"indication":"Sarcopenia","completionDate":"2023-01-20"},{"nctId":"NCT07447518","phase":"EARLY/Phase 1","title":"Comparison of Mirabegron ,Tamsulosin and Solifenacinin Relieving Double -J Stent Related Symptoms : Approspective Randmized Placebo Controlledtrial","status":"COMPLETED","sponsor":"Kafrelsheikh University","isPivotal":false,"enrollment":535,"indication":"Lower Urinary Tract Symptoms","completionDate":"2023-09-01"},{"nctId":"NCT00382135","phase":"Phase 4","title":"An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing With 20 mg Tadalafil","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":282,"indication":"Erectile Dysfunction","completionDate":"2005-12"},{"nctId":"NCT00617305","phase":"Phase 4","title":"An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Respon","status":"COMPLETED","sponsor":"Gilead Sciences","isPivotal":false,"enrollment":38,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-07"},{"nctId":"NCT00750308","phase":"NA","title":"Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi","status":"COMPLETED","sponsor":"Vanderbilt University","isPivotal":false,"enrollment":27,"indication":"Metabolic Syndrome","completionDate":"2009-05"},{"nctId":"NCT06717711","phase":"Phase 3","title":"Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","isPivotal":true,"enrollment":158,"indication":"Prostate Carcinoma, Erectile Function","completionDate":"2026-08-31"},{"nctId":"NCT05179876","phase":"Phase 3","title":"A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies","status":"RECRUITING","sponsor":"Actelion","isPivotal":true,"enrollment":280,"indication":"Hypertension, Pulmonary","completionDate":"2028-02-29"},{"nctId":"NCT02645890","phase":"Phase 1","title":"A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Profiles of CKD-397 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":false,"enrollment":36,"indication":"Benign Prostatic Hyperplasia","completionDate":"2015-12"},{"nctId":"NCT04164355","phase":"N/A","title":"Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days: a Single-centre Prospective-control","status":"COMPLETED","sponsor":"Federico II University","isPivotal":false,"enrollment":40,"indication":"Erectile Dysfunction Following Radical Prostatectomy","completionDate":"2021-04-30"},{"nctId":"NCT05955001","phase":"Phase 2","title":"A Randomized Controlled Trial to Examine the Utility of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Anatomical Endoscopic Enucleation of Prostate (AEEP)","status":"RECRUITING","sponsor":"Mansoura University","isPivotal":true,"enrollment":110,"indication":"Erectile Dysfunction, Lower Urinary Tract Symptoms","completionDate":"2025-07"},{"nctId":"NCT07391579","phase":"Phase 4","title":"Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients: A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial","status":"RECRUITING","sponsor":"Mansoura University","isPivotal":false,"enrollment":500,"indication":"Erectile Dysfunctions","completionDate":"2027-06"},{"nctId":"NCT02544880","phase":"Phase 1","title":"PDE5 Inhibition Via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase ","status":"COMPLETED","sponsor":"Donald T. Weed, MD, FACS","isPivotal":false,"enrollment":16,"indication":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer","completionDate":"2021-06-08"},{"nctId":"NCT06553924","phase":"Phase 1","title":"Single Dose Oral Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg in Healthy Adult Male Subjec","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","isPivotal":false,"enrollment":30,"indication":"PAH","completionDate":"2024-08-08"},{"nctId":"NCT01564303","phase":"NA","title":"Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study","status":"UNKNOWN","sponsor":"The Nazareth Hospital","isPivotal":false,"enrollment":80,"indication":"Contrast Media Induced Nephropathy","completionDate":"2013-02"},{"nctId":"NCT06491108","phase":"Phase 3","title":"Vardenafil Versus Tadalafil Versus Tamsulosin in Patients With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Prospective Randomized Study.","status":"RECRUITING","sponsor":"Tanta University","isPivotal":true,"enrollment":150,"indication":"Enlarged Prostate With Lower Urinary Tract Symptoms","completionDate":"2025-07-01"},{"nctId":"NCT05466695","phase":"EARLY/Phase 1","title":"Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":74,"indication":"Erectile Dysfunction and Neutrophil Lymphocyte Ratio","completionDate":"2023-08-01"},{"nctId":"NCT00540124","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and ","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":151,"indication":"Benign Prostatic Hyperplasia","completionDate":"2008-06"},{"nctId":"NCT00274430","phase":"Phase 1","title":"A Randomized Controlled Trial of the Effects of Tadalafil and Dexamethasone Versus Placebo on Pulmonary Edema Formation and Cerebral Blood Flow Autoregulation in High Altitude Newcomers With a Previou","status":"COMPLETED","sponsor":"University of Zurich","isPivotal":false,"enrollment":30,"indication":"High Altitude Pulmonary Edema","completionDate":"2003-09"},{"nctId":"NCT01937871","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Sympto","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":909,"indication":"Benign Prostate Hyperplasia, Erectile Dysfunction","completionDate":"2015-12"},{"nctId":"NCT01484431","phase":"Phase 1","title":"A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":20,"indication":"Pulmonary Arterial Hypertension","completionDate":"2019-04-03"},{"nctId":"NCT06962462","phase":"NA","title":"Effect of Daily Tadalafil Therapy on Endothelin-1 and E-Selectin in Diabetic Patients With Erectile Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"South Valley University","isPivotal":false,"enrollment":60,"indication":"Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","completionDate":"2025-08-30"},{"nctId":"NCT00421083","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess Efficacy and Safety of Tadalafil (LY450190) in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":180,"indication":"Erectile Dysfunction, Spinal Cord Injuries","completionDate":"2005-06"},{"nctId":"NCT04946162","phase":"Phase 4","title":"The Use of Tadalafil in Confirmed COVID-19 Pneumonia.","status":"WITHDRAWN","sponsor":"Santa Barbara Cottage Hospital","isPivotal":false,"enrollment":0,"indication":"COVID, Sars-CoV2","completionDate":"2020-04-20"},{"nctId":"NCT04491773","phase":"N/A","title":"Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days for More Than 6 Months: a Single-cen","status":"COMPLETED","sponsor":"Federico II University","isPivotal":false,"enrollment":54,"indication":"Erectile Dysfunction Following Radical Prostatectomy","completionDate":"2020-05-30"},{"nctId":"NCT00547287","phase":"Phase 3","title":"Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":2760,"indication":"Impotence","completionDate":"2004-05"},{"nctId":"NCT01130532","phase":"Phase 4","title":"Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":623,"indication":"Erectile Dysfunction","completionDate":"2012-01"},{"nctId":"NCT07466030","phase":"Phase 1","title":"Impact of Daily Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate :A Randomized , Single Blinded ,Controlled Trial\"","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","isPivotal":false,"enrollment":40,"indication":"BPH (Benign Prostatic Hyperplasia)","completionDate":"2028-09-01"},{"nctId":"NCT02554045","phase":"Phase 4","title":"Effects of Daily Tadalafil on Body Composition in Men With Sexual Distress","status":"COMPLETED","sponsor":"University of Roma La Sapienza","isPivotal":false,"enrollment":20,"indication":"Obesity, Sexual Dysfunction","completionDate":"2015-09"},{"nctId":"NCT01553981","phase":"Phase 3","title":"A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","isPivotal":true,"enrollment":40,"indication":"Lung Diseases, Interstitial","completionDate":"2014-05"},{"nctId":"NCT06707181","phase":"Phase 3","title":"Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones","status":"COMPLETED","sponsor":"Beni-Suef University","isPivotal":true,"enrollment":180,"indication":"Lower Ureteral Stones","completionDate":"2024-08-18"},{"nctId":"NCT00668109","phase":"Phase 3","title":"A Randomized, Open-label, Multi-center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabe","status":"COMPLETED","sponsor":"Bayer","isPivotal":true,"enrollment":614,"indication":"Erectile Dysfunction","completionDate":"2004-06"},{"nctId":"NCT01122264","phase":"Phase 4","title":"Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhib","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":770,"indication":"Erectile Dysfunction","completionDate":"2011-06"},{"nctId":"NCT01858558","phase":"Phase 2","title":"Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":102,"indication":"Multiple Myeloma","completionDate":"2019-06-19"},{"nctId":"NCT07231185","phase":"Phase 2","title":"A Phase 2 Open-Label Study to Evaluate the Efficacy, Safety, and Treatment Experience of Hezkue® and Hezkue Turbo® Compared With Select Commercially Available Sildenafil Products in Adult Men With Ere","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","isPivotal":false,"enrollment":200,"indication":"Erectile Dysfunction","completionDate":"2026-03"},{"nctId":"NCT05823506","phase":"NA","title":"Efficacy and Safety of Focused Shockwave Therapy Plus Tadalafil vs Tadalafil Alone in Patient With Erectile Dysfunction: Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Saint Petersburg State University, Russia","isPivotal":false,"enrollment":36,"indication":"Erectile Dysfunction","completionDate":"2024-02-01"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3158/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$115","description":"TADALAFIL 10 MG TABLET","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-02-08T00:00:00.000Z","mah":"ELI LILLY CO","brand_name_local":null,"application_number":"NDA022332"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-02-05T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"ANDA210145"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-26T00:00:00.000Z","mah":"TORRENT","brand_name_local":null,"application_number":"ANDA211839"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-10-07T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA207244"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-06-17T00:00:00.000Z","mah":"CMP DEV LLC","brand_name_local":null,"application_number":"NDA214522"},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":"EMEA/H/C/003787"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tadalafil Mylan","application_number":null}],"patentsNormalised":[{"patent_number":"11975006","territory":"US","patent_type":"Formulation","expiry_date":"2038-12-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12186322","territory":"US","patent_type":"Formulation","expiry_date":"2038-12-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11382917","territory":"US","patent_type":"Formulation","expiry_date":"2038-12-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11666576","territory":"US","patent_type":"Formulation","expiry_date":"2038-12-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":7,"withResults":2},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tadalafil","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:28:36.786076+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:28:36.785982+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:28:41.956107+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:28:35.909731+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tadalafil","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:28:42.326280+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:34.714506+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:34.714544+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:34.714549+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:28:43.971587+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Phosphodiesterase 5A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:43.368601+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL779/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:43.037218+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA215556","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:34.714552+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:47.038416+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL779"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}